The long-acting formulation of the schizophrenia drug ‘Invega’ has landed in general hospitals in Korea.

According to industry sources, Invega Hafyera 1092mg/1560mg (paliperidone palmitate), Janssen Korea’s extended-release injectable suspension for patients with schizophrenia that is injected every 6 months, has passed the drug committees of medical institutions in Korea, including Seoul Asan Medical Center.

Janssen has been continuously working to create a prescription environment since it was listed for reimbursement in May.

Invega Hafyera was approved by the Ministry of Food and Drug Safety in September 2022. The 1-month extended-release injectable formulation of